Citadel Advisors
GLUE icon

Citadel Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Citadel Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$505K Buy
30,700
+12,000
+64% +$229K ﹤0.01% 9282
2025
Q4 		$293K Buy
18,700
+8,600
+85% +$116K ﹤0.01% 10208
2025
Q3 		$74.8K Sell
10,100
-34,400
-77% -$182K ﹤0.01% 12010
2025
Q2 		$201K Buy
44,500
+9,600
+28% +$42.8K ﹤0.01% 10676
2025
Q1 		$162K Sell
34,900
-25,700
-42% -$158K ﹤0.01% 10749
2024
Q4 		$421K Sell
60,600
-9,100
-13% -$68.3K ﹤0.01% 8945
2024
Q3 		$369K Buy
69,700
+58,000
+496% +$293K ﹤0.01% 8875
2024
Q2 		$43.8K Sell
11,700
-3,600
-24% -$18.4K ﹤0.01% 11912
2024
Q1 		$108K Sell
15,300
-28,500
-65% -$169K ﹤0.01% 11253
2023
Q4 		$247K Buy
43,800
+37,000
+544% +$145K ﹤0.01% 9541
2023
Q3 		$32.6K Sell
6,800
-35,200
-84% -$227K ﹤0.01% 12206
2023
Q2 		$288K Sell
42,000
-900
-2% -$5.82K ﹤0.01% 9137
2023
Q1 		$334K Buy
42,900
+24,300
+131% +$169K ﹤0.01% 9160
2022
Q4 		$142K Buy
+18,600
New +$155K ﹤0.01% 10694

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citadel Advisors's GLUE Position: Q1 2026 in Review

Citadel Advisors increased its Monte Rosa Therapeutics (GLUE) stake by 450% in Q1 2026, buying an estimated $3.98M and bringing the position to 254,518 shares worth $4.19M. The position accounts for ﹤0.01% of the portfolio, ranked #4639.

Citadel Advisors first reported a position in GLUE in Q2 2021 and has held it in 19 quarters since. The position peaked at $7.79M in Q3 2022. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Citadel Advisors held 254,518 shares of Monte Rosa Therapeutics worth $4.19M as of Q1 2026.
  • Citadel Advisors bought 208,255 Monte Rosa Therapeutics shares in Q1 2026, an estimated $3.98M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4639 holding.
  • Citadel Advisors first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Citadel Advisors's Monte Rosa Therapeutics position peaked at $7.79M in Q3 2022.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.